Picture this: It’s Monday morning at dental headquarters in Irvine, California. Coffee in hand, a handful of Biolase engineers are troubleshooting a stubborn dental laser while emails pour in from worried customers. Over the past year, the room’s mood has done a complete 180 — swinging from nervous whispers about bankruptcy to a cautious optimism under new leadership. So what actually happened to Biolase, the once high-flying dental laser giant? Did they crash and burn, or just pull off a rare business escape act?
Let’s trace the chaos with a sharp eye (and zero sugar-coating).
Biolase’s Financial S.O.S. — Crashing Into Bankruptcy
The warning lights started blinking early — you could see them in the earnings reports. Think: quarter after quarter of red ink, cash bleeding faster than revenue trickled in. By October 2024, things reached DEFCON 1. Biolase filed for Chapter 11 bankruptcy in Delaware. The core issue? Straight-up liquidity trouble.
Here’s what tipped the scales: Sales stalled, while costs — from R&D to sales commissions to keeping the factory lights on — kept stacking up. To keep payroll running through the bankruptcy mess, Biolase scored $2.5 million in what’s called “debtor-in-possession” financing. It’s like a bank loan, but with stricter rules and the goal of preserving value for customers and creditors (and maybe, just maybe, giving the business one last shot).
Chapter 11 isn’t code for “closing up shop,” though. It’s more like a hospital ER for broken companies: freeze some debts, keep the essential organs working, and see if a turnaround is possible. For Biolase, the looming problem wasn’t just money. It was the credibility hit. Dentists who’d spent years relying on Biolase’s lasers were suddenly calling, “So, uh, am I getting warranty support on this $50,000 machine… or was that a farewell tour?”
Nasdaq Delisting — And the Shame That Comes With It
If bankruptcy was the heart attack, losing their place on the Nasdaq was the public shaming. In June 2024, the Nasdaq Stock Market swung the axe: Biolase was officially delisted. The offense? Failing to meet minimum bid price and equity thresholds.
Numbers make it plain. Biolase’s stock struggled to stay above $1 a share, and its net worth dropped far below Nasdaq’s minimum safety net (think: millions underwater). For shareholders and execs alike, it meant more than wounded pride. Without a major market listing, raising capital gets much harder, and every vendor suddenly double-checks your credit.
When stocks tank and the market moves you to the “penny stocks” corner, investors don’t exactly line up to roll the dice. Delisting is a loud signal. It tells competitors, “Now’s your chance!” And it tells bankers, “Hope you’re not too exposed.”
The Asset Sale — Everything Must Go (But Not Everything Did)
Then came the sale. To survive bankruptcy, Biolase scheduled an auction of its tangible and intangible assets. The top bidder, ironically, wasn’t some private equity giant, but Sonendo — a dental industry competitor. They agreed to snap up most assets for $14 million.
For context: $14 million, in dental tech land, buys you patents, factory equipment, and a customer list that took decades to build. But it’s a far cry from Biolase’s peak valuation. Bankruptcy wipes out old shareholders and gives buyers a fresh start — but the folks caught in between (employees, small vendors) usually suffer whiplash.
Curiously, the sale didn’t shut down every Biolase operation. The business continued in a wounded state, steadily delivering lasers, training, and support — but with more uncertainty than a wisdom tooth extraction under local anesthesia.
MegaGen Steps In — Biolase Gets a New Owner and a New Brain
Just when it looked like Biolase might fade away, a twist. In November 2024, MegaGen — a global leader in dental implants, based out of South Korea — swooped in and acquired Biolase’s business. New owner, new attitude. The company named Dr. Kwang Bum Park as CEO, a veteran with a reputation for turning “problem children” brands into profitable siblings.
MegaGen didn’t just buy machines and blueprints. They bought relationships: tens of thousands of dentists, international distribution partners, and a hard-won reputation for laser innovation. Under the new bosses, the first order of business was sending a simple message: “We’re not disappearing. Your lasers still have a home.”
And for Dr. Park, the opportunity was obvious. Even a bruised-but-still-breathing Biolase had something worth saving — provided you could refocus it and spend less time fighting fires, more time building partnerships.
So Wait — Is Biolase Out of Business?
Short answer? No. Biolase as you remember it (the old corporate shell) is gone. But the brand, the products, and the tech soldiers on. Post-acquisition, the company made an official statement in July 2025:
“No, Biolase is not going out of business. Biolase is stronger than ever, now backed by MegaGen.”
That’s a bold claim, but let’s break it down. There’s a shiny new balance sheet, so daily cash flow problems have mostly faded. The support teams didn’t skip a beat. And under MegaGen, there’s a fresh push to keep innovating — not just patching up holes, but rolling out new products.
For dentists debating whether to keep buying or servicing Biolase machines, the answer is practical: the company is active, warranty support is ongoing, and in MegaGen’s hands, they’ll likely play a more stable (if less flashy) game.
The Timeline — Biolase’s Year From Hell (And Recovery)
Here’s a quick cheat sheet of how things fell apart, then (sort of) came back together:
| Event | Date | Details/Outcome |
|---|---|---|
| Nasdaq Delisting | June 2024 | Failed financial listing standards, chronic losses |
| Chapter 11 Bankruptcy Filing | Oct 2024 | Asset sale, continued operations during proceedings |
| Asset Sale to Sonendo | Oct 2024 | $14M agreement, part of bankruptcy process |
| Acquisition by MegaGen | Nov 2024 | New ownership, new CEO, reorganization |
| Official Statement | July 2025 | Declared “not going out of business” under MegaGen |
It’s rare, but not unheard of, for a company to ride bankruptcy, a buyout, and a reorganization in under 12 months. (The sweet spot for a “phoenix” rebirth? Aggressively clear debts, hire fresh leadership, and have a product customers still love.)
What This Means for Biolase Customers and Partners
Maybe you’re a dentist wondering if you just bought a $60,000 brick. Maybe you’re a distributor who’s spent years pushing Biolase’s lasers to clinics. The day-to-day here is pretty simple:
1. Product Support: Still running. Biolase is delivering parts, updates, and training as before.
2. Warranty Coverage: As of summer 2025, contracts and warranty repairs are being honored.
3. New Developments: MegaGen’s muscle could mean faster product upgrades and more robust customer service.
For industry watchers, there’s also a little lesson: Don’t write off a business just because it filed for bankruptcy, or switched owners. The hard practical work — calling customers, shipping products, returning support calls — matters just as much as financial theatrics.
How Biolase Plans to Win — Not Just Survive
Now, the question facing Dr. Park and the new crew is whether Biolase will just limp along, or actually thrive. Turns out, this isn’t just about plugging balance sheet holes. It comes down to two things:
First, MegaGen brings bigger pockets and R&D muscle. If you have a blockbuster dental laser idea, you need funding and risk tolerance. Both tended to vanish in Biolase’s old, over-leveraged days.
Second, credibility. In medical tech, reputation is everything. Dentists hate moving targets — they want a supplier that answers questions and upgrades products, not one reorganizing in court every year. A stable parent company is a powerful signal.
MegaGen’s team made a clear pitch to the market: Biolase will focus hard on supporting dental partners, fueling laser innovations, and not just “hanging on by a thread.” For business owners big and small — whether you’re running a ten-seat dental practice or a Shopify store — there’s real value in turning chaos into an “I’ve seen worse” story.
Lessons in Corporate Survival, Grit — and Plain Old Luck
Not every brand gets a second act like this. If you’re a small business owner stressed about missing a loan payment, take heart: Survival sometimes means admitting you hit a wall, clearing the decks, and letting outside help take the wheel. That, plus keeping relationships alive at all costs.
Biolase isn’t the first company to pull back from the brink, and it won’t be the last. If you’re curious how other companies have managed the same wild swings — from bankruptcy to buyout — check this hub of business comebacks and cautionary tales. The sweet spot, for Biolase now, is blending MegaGen’s big-company discipline with the nimbleness of a startup.
The Bottom Line — Where Does Biolase Stand Today?
Biolase isn’t out of business. It’s just done business the hard way, weathering bankruptcy, asset sales, and an owner swap — all in 12 roller-coaster months. The brand, the staff, and most importantly the customer relationships survived (albeit a little battered).
If you’re betting on Biolase’s future? The company’s odds look far better than they did this time last year — thanks to MegaGen’s stabilizing hand, a new executive team, and the simple fact that thousands of clinics still believe in the product.
Call it survival, call it reinvention, call it proof that dentistry has more cliffhangers than you’d expect. Biolase today isn’t the same old company, which, if you’re paying attention to what works long-term in business, may yet turn out to be its biggest advantage.
Also Read:
